Further research that elucidates the possible mechanism of PI3K inhibition, intrinsic and acquired resistance, is essential to enhance the durability of clinical benefit with targeted combination treatment tailored to specific subtypes of breast cancer and the mutational status of the patients. This evidence concerns the gene PIK3CB and breast carcinoma.